Angioedema occurs in up to 5% of patients on angiotensin-converting enzyme inhibitor (ACEI) therapy receiving IV rtPA.1 A 58-year-old man taking the combination ACEI amlodipine/benazepril received IV rtPA for clinical left middle cerebral artery territory acute infarction, NIHSS 9. Head CT was unremarkable. He developed orolingual angioedema 5 minutes after rtPA infusion was completed (figure). There was no airway compromise or hemodynamic instability to suggest anaphylactic reaction. Symptoms were treated with dexamethasone and a histamine antagonist. The angioedema resolved completely over the next 48 hours, as did his neurologic deficits.
Figure. This patient developed severe orolingual angioedema involving predominantly the lower lip with apparent bilateral onset within 5 minutes of completing rtPA infusion. Erythrocyte sedimentation rate, immunoglobulin E, and complete cell count with differential were unremarkable.
Footnotes
-
Disclosure: The authors report no conflicts of interest.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.